Lilly Stock Drops Lowwer Foundayo Claims an Oral Edge
Eli Lilly NYSE:LLY, the obesity and diabetes drugmaker, slipped about 0.3% to $1,181.45 at 10.15 EST time in Tuesday morning trading after it made a fresh case for its Foundayo pill against a higher dose of Novo Nordisk's oral semaglutide. The claim sounds strong. The comparison needs a closer look…